Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

IMPORTANCE: Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased bleeding and dyspnea. OBJECTIVE: To compare the...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA Intern Med
Главные авторы: Turgeon, Ricky D., Koshman, Sheri L., Youngson, Erik, Har, Bryan, Wilton, Stephen B., James, Matthew T., Graham, Michelle M.
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2020
Предметы:
Original Investigation
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990835/
https://ncbi.nlm.nih.gov/pubmed/31930361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2019.6447
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы